Baxter International Inc.: PharmaVitae Report

Report Summary

This analysis examines the historical and forecast performance for Baxter in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

• Gain insight into Baxter's strategic outlook across the next 6 years
• Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for Baxter over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

• Benchmark Baxter's performance against key rivals in the prescription pharmaceutical sector
• Assess the importance of Baxter's "wild card" Gammagard for Alzheimer's disease (currently in Phase III trials) in driving sales growth out to 2016

Table of Contents

ABOUT THIS REPORT
PharmaVitae Explorer database
Chapter structure
Strategic insight
Company introduction
Sales analysis
Financial analysis
Product analysis
Data sourcing
Analyst consensus

EXECUTIVE SUMMARY
Key findings
Baxter International prescription pharma sales outlook
Baxter International financial outlook
Key developments
Recent developments
SWOT: Baxter International

STRATEGIC INSIGHT
Key findings
Baxter’s hemophilia market share under threat
Externally sourced growth
Lifecycle management strategy – launch of Advate
Stuttering hemophilia franchise performance puts extra pressure on Gammagard (CNS)

COMPANY INTRODUCTION
Key findings
Background
Key corporate developments
M&A history
Current corporate structure

SALES ANALYSIS
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2004–16
Product analysis
Product analysis, 2004–10
Product analysis, 2010–16
Therapy area analysis
Geographic analysis
Launch/core/expiry analysis
Explanation of launch/core/expiry analysis
Launch analysis, 2010–16
Core analysis, 2010–16
Expiry analysis, 2010–16
Generics analysis, 2010–16
Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis

FINANCIAL ANALYSIS
Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004–10
Operating costs and profit analysis
Operating costs and profit analysis, 2004–10
Operating cost ratio and profit margin analysis, 2004–10
Operating cost ratio and profit margin analysis, 2010–16
Operating costs and profit analysis, 2010–16

PRODUCT ANALYSIS
Overview
Antibody therapy (including Gammagard)
Gammagard (CNS)
Recombinate/Advate

APPENDIX
References
Datamonitor reports

List of Tables

Table: Baxter International – key product overview ($m), 2010–16
Table: Baxter International’s financial performance ($m), 2010–16
Table: Key hemophilia treatment sales ($m), 2010–16
Table: Baxter International acquisitions, 1990–2011
Table: Baxter International product portfolio overview ($m), 2004–10
Table: Baxter International product portfolio overview ($m), 2010–16
Table: Baxter International prescription pharmaceutical sales, by therapy area ($m), 2010–16
Table: Baxter International prescription pharmaceutical sales, by geographic region ($m), 2010–16
Table: Baxter International launch portfolio overview ($m), 2010–16
Table: Baxter International core portfolio overview ($m), 2010–16
Table: Baxter International expiry portfolio overview ($m), 2010–16
Table: Baxter International generics portfolio overview ($m), 2010–16
Table: Baxter International prescription pharmaceutical sales, by molecule type ($m), 2010–16
Table: Baxter International prescription pharmaceutical sales, by source ($m), 2010–16
Table: Total Baxter International sales, by business unit ($m), 2004–10
Table: Baxter International operating revenues, costs, and profit ($m), 2004–10
Table: Baxter International operating cost ratios and profit margin (as a percentage of total revenues), 2004–10
Table: Baxter International operating cost ratios and profit margin (as a percentage of total revenues), 2010–16
Table: Baxter International operating revenues, costs, and profit ($m), 2010–16
Table: Key product sales ($m), 2010–16
Table: Antibody therapy: overview
Table: Antibody therapy : sales forecast ($m), 2010–16
Table: Gammagard (CNS): overview
Table: Gammagard (CNS) : sales forecast ($m), 2010–16
Table: Recombinate/Advate: overview
Table: Recombinate/Advate : sales forecast ($m), 2010–16

List of Figures

Figure: The PharmaVitae Explorer
Figure: Baxter International prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16
Figure: Baxter International’s financial performance ($m), 2004–16
Figure: SWOT: Baxter International
Figure: Blood coagulation factors market share (%), 2010 and 2016
Figure: Baxter prescription sales performance ($m), scenario analysis, 2004–16
Figure: Baxter timeline
Figure: Current corporate structure
Figure: Baxter International business structure (% of total revenues), 2004–10
Figure: Baxter International prescription pharmaceutical performance, sales ($m) and growth rate (%), 2004–16
Figure: Baxter International’s key product sales ($m), 2004–16
Figure: Baxter International key sales growth drivers and resistors ($m), 2004–10
Figure: Baxter International key sales growth drivers and resistors ($m), 2010–16
Figure: Baxter International prescription pharmaceutical sales, by therapy area ($m), 2004–16
Figure: Baxter International prescription pharmaceutical sales, by geographic region ($m), 2004–16
Figure: Baxter International launch/core/expiry configuration ($m), 2010–16
Figure: Baxter International prescription pharmaceutical sales, by molecule type ($m), 2004–16
Figure: Baxter International prescription pharmaceutical sales, by source ($m), 2004–16
Figure: Baxter International operating revenues, costs, and profit ($m), 2004–16